MapLight Therapeutics shares surge 29.48% after-hours after Stifel Nicolaus maintains Buy rating and Leerink initiates Outperform.

Wednesday, Dec 3, 2025 5:28 pm ET1min read
MPLT--
MapLight Therapeutics surged 29.48% in after-hours trading following positive analyst ratings. Stifel Nicolaus analyst Paul Matteis reaffirmed a Buy rating on November 24, maintaining a bullish stance on the stock, while Leerink initiated the stock with an Outperform rating, citing strategic positioning and promising investment potential. The dual analyst endorsements, emphasizing MapLight’s favorable outlook and growth prospects, likely fueled the sharp post-market rally.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet